AGF Management says CEO Kevin McCreadie has died, Judy Goldring named successor
AGF executive chairman Blake Goldring says the company was devastated by the loss and that McCreadie's impact on the organization was profound and will be lasting.
The company say McCreadie will be remembered for his passion for investment management and his focus on developing and nurturing talent for the future.
AGF named Judy Goldring, AGF's president and head of global distribution, as CEO, effective immediately.
Judy Goldring joined AGF in 1998 as general counsel and has held several roles with increasing responsibility across the firm.
AGF has over $53 billion in total assets under management and fee-earning assets for more than 815,000 investors.
Monday Mornings
The latest local business news and a lookahead to the coming week.
This report by The Canadian Press was first published July 3, 2025.
Companies in this story: (TSX:AGF.B)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
HLS Therapeutics Announces New Credit Agreement
TORONTO, Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that the company has entered into a new Credit Agreement (the "Agreement") with National Bank of Canada ("National Bank") as administrative agent which provides for committed credit facilities denominated in Canadian dollars of up to CAD $107 million (USD ~$77.5 million). National Bank serves as administrative agent and lead arranger, with the Toronto-Dominion Bank, Royal Bank of Canada, and Innovation Federal Credit Union as syndicate members. The Agreement replaced HLS's credit facility with JP Morgan Chase Bank, N.A. which had a maturity date of August 11, 2026. On closing, the proceeds from the new term facility were used to repay the Company's existing credit agreement in full. The new Agreement has a maturity date of August 19, 2029. The Agreement consists of a CAD $79 million term credit facility, a CAD $14 million delayed draw facility and a CAD $14 million revolving credit facility. In addition, HLS can increase facilities further through an uncommitted CAD $40 million accordion facility (subject to Lender agreement). Interest on the Agreement accrues at a rate per month equal to the sum of the Canadian Overnight Repo Rate Average ("CORRA") plus a range of 2.25% to 3.50% depending on the leverage ratio of the Company at the time. Interest rate spreads are 25-50 basis points below the rate in the Company's prior credit agreement, providing improved cash flow through reduced interest expense. The debt is denominated in Canadian dollars, creating a natural currency hedge against the Company's predominantly Canadian operations. In addition to the interest rate spread savings detailed above, HLS will achieve further interest rate savings in excess of 100 basis points based on current market interest rates, as a result of the differential between US dollar and Canadian dollar base rates. "We are pleased to finalize this new credit agreement with National Bank and our syndicate partners, which reflects their confidence in our outlook," said John Hanna, CFO of HLS Therapeutics. "The Agreement delivers improved terms that reflect our strengthened financial position and provides enhanced financial flexibility and cash flow to pursue our capital allocation priorities such as share buybacks and portfolio expansion." ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated August 13, 2025, both of which have been filed on SEDAR+ and can be accessed at Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE HLS Therapeutics Inc.
Cision Canada
an hour ago
- Cision Canada
Three Cascades leaders feature in the 2025 Top 10 Under 40 list for the Canadian pulp and paper industry Français
KINGSEY FALLS, QC, Aug. 20, 2025 /CNW/ - Cascades Inc. (TSX: CAS), a leader in environmentally responsible packaging and hygiene product recovery and manufacturing, is thrilled to announce that three of its young leaders have made Pulp & Paper Canada's Top 10 Under 40 list, which recognizes excellence, leadership and innovation among young professionals in the pulp and paper industry across the country. Louis Chauvette is Technical Director in the Engineering and Operational Excellence team. Since joining Cascades, Louis has shown a rare combination of technical expertise, strategic thinking and people-first leadership. He has spearheaded major process optimization projects generating significant gains in terms of energy efficiency, production quality and environmental performance. Louis embodies the values of collaboration, continuous improvement and strategic vision through his ability to motivate others and connect the Operations, R&D and executive teams. Benjamin Granger works as Director, Demand and Supply Planning for the Tissue sector. His journey from intern to manager is a testament to his determination, talent and leadership. After joining Cascades, Benjamin proved himself a strategic leader. Through his knowledge of demand forecasting, inventory optimization and production planning, our supply chain grew more agile and efficient in an ever-changing market, generating tangible value across Cascades. His collaborative approach, analytical mindset and commitment to continuous improvement are valuable assets to our organization. Leslie Ruggeri is Plant Manager, Succession at the St. Marys plant. After obtaining her bachelor's degree in sociology and a human resource management certificate, she launched her career in human resources and recruiting before moving on to operations. Her versatility, natural leadership skills and ability to connect with people have made her transition a promising one. Her atypical journey combining human expertise and operational excellence brings new perspectives to Cascades. She's an ambitious leader boasting cross-functional skills and a true commitment to community development. These three Cascaders represent the future of the industry through their leadership and significant contribution to the pulp and paper industry's growth. Their inclusion on this list is a testament not only to their individual talent, but also to Cascades's collective strength. "This recognition is truly inspirational and showcases the exceptional quality of our new talent. The passion, discipline and vision they bring to the job every day help us grow our organization and build a more sustainable industry," said Hugues Simon, President and CEO of Cascades. "On behalf of Cascades, I would like to extend our sincerest congratulations." Founded in 1964, Cascades offers sustainable, innovative and value-added solutions for packaging, hygiene and recovery needs. The company employs approximately 9,600 women and men in a network of 66 production units, including 17 recovery and recycling units that are part of the company's corporate operations and joint ventures located in North America. With its participative management, half a century of experience in recycling, and ongoing efforts in research and development as driving forces, Cascades continues to deliver the innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS. SOURCE Cascades Inc.
Toronto Star
2 hours ago
- Toronto Star
Goodfood Announces CEO Transition and New Board Chair
MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) — Goodfood Market Corp. ('Goodfood' or the 'the Company') (TSX: FOOD) announced today changes to its management and board of directors. Jonathan Ferrari, Goodfood's co-founder, Chair and CEO, will be stepping down from his executive roles, effective immediately. Mr. Ferrari will continue to serve as a director on the Board.
